Amgen shares climb after judge upholds Repatha patents
A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →
Read More →
Corporate tax cut could fuel biotech mergers, acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Oak Park Shopping Center in Thousand Oaks sells for $28.3 million
The Oak Park Shopping Center in Thousand Oaks was sold for $28.3 million, CBRE Group announced on Jan. 5. New Oak Park LLC, represented by CBRE’s Alex Kozakov, Patrick Wade, Larry Tanji and Scott Siegel, sold the 74,300-square-foot center to a private investor, who was represented by Paley Commercial Real Estate. The center on Lindero Read More →
Read More →Teledyne gets contract for underwater vehicles that remove explosives
A subsidiary of Thousand Oaks industrial conglomerate Teledyne Technologies secured a multi-million dollar contract with the U.S. Department of Defense to deploy underwater vehicles to disable and remove explosives, the company announced Jan. 3. The amount of the contract was not disclosed. Teledyne SeaBotix, a manufacturer of underwater observation class remotely-operated vehicles, will deliver 60 Read More →
Read More →Interest rate hike could trigger tri-county homebuying spree
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen seeks to market osteoporosis drug in Japan
Thousand Oaks biotech giant Amgen is seeking marketing approval in Japan for osteoporosis drug romosozumab, the company announced on Dec. 20. Amgen submitted the request to the Pharmaceuticals and Medical Devices Agency in Japan, where an estimated 12 million people have a high risk of bone fracture. The company is co-developing the drug worldwide with Euronext Read More →
Read More →Bank of America hires new market president
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →
Sponsored content:
2015-2016 Giving Guide
